WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2023 on Friday, March 15, 2024. The results will be released after the market close on Friday, March 15 and the company will host a conference call on Monday, March 18 at 10:00am Eastern Time.
Conference Call and Webcast Information
| Conference call: | Monday, March 18, 2024 at 10:00 AM Eastern Time |
| Toll Free: | 1-877-877-1275 |
| International: | 1-412-858-5202 |
| Webcast: | Webcast | Fourth Quarter 2023 Financial Results and Business Update Conference Call (choruscall.com) |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.86 |
| Daily Change: | 0.02 2.61 |
| Daily Volume: | 63,348 |
| Market Cap: | US$8.110M |
May 15, 2025 March 21, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
